Simulations Plus (NASDAQ:SLP) Stock Price Up 3.9% - What's Next?

Shares of Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) traded up 3.9% during mid-day trading on Monday . The stock traded as high as $34.40 and last traded at $33.97. 284,631 shares changed hands during trading, an increase of 46% from the average session volume of 194,371 shares. The stock had previously closed at $32.69.

Wall Street Analysts Forecast Growth

SLP has been the topic of several research analyst reports. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. StockNews.com cut Simulations Plus from a "hold" rating to a "sell" rating in a research report on Monday, April 14th. Finally, KeyCorp lifted their price objective on Simulations Plus from $32.00 to $40.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $50.00.

Simulations Plus Stock Down 1.1 %

The stock has a market cap of $713.94 million, a PE ratio of 88.75 and a beta of 1.13. The firm has a 50-day simple moving average of $28.43 and a 200-day simple moving average of $30.26.

Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business had revenue of $22.43 million for the quarter, compared to analysts' expectations of $21.93 million. During the same quarter in the prior year, the firm posted $0.20 EPS. The firm's quarterly revenue was up 22.5% on a year-over-year basis. On average, research analysts expect that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is owned by corporate insiders.

Institutional Trading of Simulations Plus

A number of large investors have recently modified their holdings of SLP. Barclays PLC increased its position in shares of Simulations Plus by 390.6% in the third quarter. Barclays PLC now owns 28,473 shares of the technology company's stock worth $911,000 after purchasing an additional 22,669 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Simulations Plus in the 4th quarter worth approximately $719,000. Geode Capital Management LLC increased its holdings in shares of Simulations Plus by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company's stock worth $14,367,000 after buying an additional 18,924 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Simulations Plus by 106.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock valued at $1,517,000 after buying an additional 24,371 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Simulations Plus during the 4th quarter worth $330,000. Institutional investors own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.